InflaRx N.V. (IFRX : NASDAQ)
Common Stock
$150.00
USD
+148.11 (7836.51%)
Last updated: 2026-09-28
Follow IFRX
IFRX
InflaRx N.V.
WealthAwesomePerformance
1 Day
+7836.51%
1 Week
+6975.47%
1 Month
+6626.46%
YTD
+8141.76%
Key Statistics
Market Cap
$278.53M
52W High
$150.00
52W Low
$0.80
P/E Ratio
-
50 Day MA
$2.00
200 Day MA
$1.57
Beta
2.54
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/28/2026 | $145.00 | $150.00 | $141.00 | $150.00 | $150.00 | 5 |
| 9/25/2026 | $1.94 | $2.04 | $1.87 | $1.89 | $1.89 | 399,901 |
| 9/24/2026 | $1.97 | $2.02 | $1.89 | $1.93 | $1.93 | 509,220 |
| 9/23/2026 | $2.08 | $2.09 | $1.96 | $1.96 | $1.96 | 564,756 |
| 9/22/2026 | $2.12 | $2.19 | $2.04 | $2.08 | $2.08 | 571,245 |
| 9/21/2026 | $2.11 | $2.19 | $2.06 | $2.12 | $2.12 | 345,138 |
| 9/18/2026 | $2.07 | $2.11 | $2.03 | $2.09 | $2.09 | 292,676 |
| 9/17/2026 | $2.05 | $2.10 | $1.98 | $2.06 | $2.06 | 657,282 |
| 9/16/2026 | $2.02 | $2.07 | $1.99 | $2.04 | $2.04 | 821,160 |
| 9/15/2026 | $2.12 | $2.17 | $1.99 | $2.02 | $2.02 | 579,599 |
Analyst Price Targets
Based on 7 analysts covering IFRX · as of Sep 28, 2026
Wall Street analysts forecast IFRX stock price to fall 94.8% over the next 12 months.
Consensus
Strong Buy4.57 / 5.00
Avg. Target
US$7.79
-94.8% Upside
Previously US$7.77 on Sep 25, 2026
Current Price
US$150.00
Last close
Analyst Breakdown (7 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IFRX's historical volatility
30-Day Vol
1270.6%
Annualized
90-Day Vol
832.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$179.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$159.20 | US$1.99 – US$12762.27 |
| 60 trading days | US$168.96 | US$0.34 – US$83259.84 |
| 90 trading days | US$179.33 | US$0.09 – US$355995.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Financials
- Revenue (TTM)
- $-10,101
- EBITDA
- $-35.64M
- Profit Margin
- 0.00%
- ROE (TTM)
- -38.52%
- EPS (Diluted)
- -0.57
- Book Value
- 1.15
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About IFRX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DCX | Digital Currency X Technology Inc. | $6.17 | +12491.84% |
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.44 | +12100.00% |
| CTNT | Cheetah Net Supply Chain Service Inc. Class A Common Stock | $3.60 | +11150.00% |
| GMEX | GMEX ROBOTICS CORPORATION | $3.24 | +7880.30% |
| FBGL | FBS Global Limited Ordinary Shares | $4.30 | +1019.79% |
| KOD | Kodiak Sciences Inc | $89.92 | +177.96% |
| LFCR | Lifecore Biomedical Inc. | $6.52 | +55.24% |
| CLRO | ClearOne Inc | $5.10 | +47.83% |